Background: Epithelial ovarian cancer remains one of the leading variants of gynecological cancer with a high mortality rate. Feasibility and technical competence for screening and detection of epithelial ovarian cancer remain a major obstacle and the development of point of care diagnostics (POCD) may offer a simple solution for monitoring its progression. Cathepsins have been implicated as biomarkers for cancer progression and metastasis; being a protease, it has an inherent tendency to interact with Cystatin C, a cysteine protease inhibitor. This interaction was assessed for designing a POCD module. Methods: A combinatorial approach encompassing computational, biophysical and electron-transfer kinetics has been used to assess this protease-inhibitor interaction. Results: Calculations predicted two cathepsin candidates, Cathepsin K and Cathepsin L based on their binding energies and structural alignment and both predictions were confirmed experimentally. Differential pulse voltammetry was used to verify the potency of Cathepsin K and Cathepsin L interaction with Cystatin C and assess the selectivity and sensitivity of their electrochemical interactions. Electrochemical measurements indicated selectivity for both the ligands, but with increasing concentrations, there was a marked difference in the sensitivity of the detection. Conclusions: This work validated the utility of dry-lab integration in the wet-lab technique to generate leads for the design of electrochemical diagnostics for epithelial ovarian cancer.
7 December 2021 in Current Protein & Peptide Science
Epithelial ovarian cancer (EOC) is a chronic and degenerative disease propelled by a mutation in BRCA1/2 genes, familial history, smoking and polycystic ovary syndrome. Although the lifetime risk of ovarian cancer is low, yet it is the fifth leading cause of cancer-related deaths. Surprisingly, EOC represents 90% of all ovarian cancers, out of which 70% of women are diagnosed with the malignancy at its advanced III-IV stages. Early detection may increase the life expectancy up to 5 years. Thus, it has become the need of the hour to attain improvement of clinical outcomes of EOC and improve the life expectancy of patients. A plethora of proteins in different biological fluids may serve as prospective identifiers for the disease. Over the years, accurate identification of proteins secreted by EOC cells has been perfected by in vitro and in silico state-of-theart technologies. Multivariate test, consisting of histo-pathological data in combination with protein biomarker panel has paved way for enhanced and accurate assessment of EOC; still, there is a chance of further improvement. This review encompasses the advances made in ovarian cancer biomarker discovery and demonstrates their potential usefulness for the design of early diagnostics of EOC.
Chronic kidney disease (CKD) afflicts 850 million people worldwide, with an estimate that it is the 5th highest cause of years of life lost (YLLs). Standard confirmatory procedures for disease are blood and urine analysis with ultrasound for confirmation. Neutrophil gelatinase-associated lipocalin (NGAL) has been established as a prognostic biomarker, especially for the pre-clinical stages of CKD, thus presenting itself as a dependable predictor of the progression. With the aim of designing diagnostics, fatty acids were explored as potential biorecognition elements for the selective capture of NGAL. Three fatty acids—linoleic acid, arachidonic acid, and retinoic acid—were shortlisted as plausible candidates based on their known affinity toward lipocalin family proteins. Docking followed by molecular dynamics simulations were employed to evaluate the binding affinity and stability of each complex. Among them, linoleic acid exhibited the most favorable interaction, as evidenced by the lowest binding free energy. Subsequently, fluorescence and electrochemical techniques—square-wave voltammetry, differential pulse voltammetry, cyclic voltammetry, and electrochemical impedance spectroscopy (EIS)—were systematically compared for qualitative and quantitative checking of the accuracy of NGAL detection. Amongst the electrochemical techniques, differential pulse voltammetry DPV demonstrated superior analytical performance with an LOD of 0.05 ng/mL with a sensitivity of 23.2 µA/cm2/pg. To the best of our knowledge, this is the first report of a fatty acid-based biosensor platform for NGAL detection, presenting a novel approach for CKD diagnostics. The sensitivity obtained is comparable with available NGAL detection methods yet cost-effective and robust.